Menu

Berlin Cures
Pipeline – BC 007
Contact
Jobs
The Team

Home / Uncategorized / Preclinical tests of Beta1-AAB elimination with an aptamer

Preclinical tests of Beta1-AAB elimination with an aptamer

Preclinical testing of Beta1-elimination with an aptamer

NEWS and scientific papers

Long-Covid Patient Succesfully Treated With BC 007 — Long-Covid Patient erfolgreich mit BC 007 behandelt
New paper: Functional autoantibodies against G-protein coupled receptors in patients with persistent post-COVID-19 symptoms
New Paper: Results of the Phase 1 study with BC 007
New Paper: The DNA-Based Drug BC 007 neutralizes agonistically acting autoantibodies directed against G protein–coupled receptors
NEWS: Berlin Cures announces start of Phase 2a for its DNA-based neutralizer of ß1-adrenoceptor autoantibodies
NEWS: Berlin Cures’ Steering Committee is Assembled to Facilitate the Design and Implementation of Phase 2 Study of BC 007
New paper: Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy
NEWS: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy
NEWS: Berlin Cures Announces Formation of Scientific Advisory Board
NEWS: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

Copyright © 2021 Berlin Cures GmbH

Top